ADIAL PHARMACEUTICALS INC
ADILNASDAQ🏆 #3730 by market capEarnings Aug 11US Equity
$364.28▼ $21.86 (−6.00%)
Simulated price1h—
24h▼ 6.0%
7d—
14d—
30d—
1y—
🏦Market Cap
$9M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
43
Weak
No chart data available for ADIL.
Trading Snapshot
- Day Range
- $362.53 – $369.47
- 52-Week Range
- $1.31 – $249.81
- Volume
- $1.64B
- Avg Volume
- $1.88B
- Shares Outstanding
- 2.6M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $923,887
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-9.93
- Dividend Yield
- —
Why Investors Own ADIL
- ✓High-growth profile — revenue up +36.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 63% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$4M▲ +36.2% YoY
Gross Margin (TTM)
63.4%▲ +2.7% YoY
Operating Income (TTM)
$787,234▲ +36.2% YoY
Free Cash Flow (TTM)
$1M▲ +36.2% YoY
About ADIAL PHARMACEUTICALS INC
A company profile for ADIAL PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
43/100
Analyst Price Target
ⓘAverage Target
$452.93
▲ +24.3% Upside
High Target$501.83
Low Target$336.49
Based on 12 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
ADIAL PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift ADIL price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
ADIAL PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.